Sol-Gel Technologies (NASDAQ:SLGL – Get Free Report) and Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, valuation, dividends and analyst recommendations.
Insider and Institutional Ownership
26.2% of Sol-Gel Technologies shares are held by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are held by institutional investors. 66.5% of Sol-Gel Technologies shares are held by insiders. Comparatively, 5.0% of Milestone Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Sol-Gel Technologies and Milestone Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sol-Gel Technologies | -910.14% | -44.05% | -36.96% |
| Milestone Pharmaceuticals | N/A | -288.33% | -58.27% |
Analyst Ratings
This is a breakdown of recent ratings and price targets for Sol-Gel Technologies and Milestone Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sol-Gel Technologies | 1 | 0 | 4 | 2 | 3.00 |
| Milestone Pharmaceuticals | 1 | 1 | 4 | 1 | 2.71 |
Sol-Gel Technologies currently has a consensus target price of $197.50, indicating a potential upside of 255.69%. Milestone Pharmaceuticals has a consensus target price of $6.40, indicating a potential upside of 930.60%. Given Milestone Pharmaceuticals’ higher probable upside, analysts clearly believe Milestone Pharmaceuticals is more favorable than Sol-Gel Technologies.
Risk & Volatility
Sol-Gel Technologies has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500. Comparatively, Milestone Pharmaceuticals has a beta of 1.07, indicating that its share price is 7% more volatile than the S&P 500.
Earnings & Valuation
This table compares Sol-Gel Technologies and Milestone Pharmaceuticals”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sol-Gel Technologies | $19.39 million | 9.36 | -$6.13 million | ($5.64) | -9.85 |
| Milestone Pharmaceuticals | $1.55 million | 49.88 | -$63.06 million | ($0.69) | -0.90 |
Sol-Gel Technologies has higher revenue and earnings than Milestone Pharmaceuticals. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Sol-Gel Technologies beats Milestone Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
About Sol-Gel Technologies
Sol-Gel Technologies is an Israel-based dermatology company that develops topical treatments for skin conditions. Its proprietary technology uses silica-based microencapsulation to formulate active ingredients for topical use. The company’s products include Epsolay, a benzoyl peroxide cream approved in the United States for inflammatory lesions of rosacea, and Twyneo, a topical combination of tretinoin and benzoyl peroxide approved for acne vulgaris. Sol-Gel has pursued commercialization and licensing opportunities in the United States and other markets.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cardiovascular conditions. Its work centers on therapies intended to give patients and caregivers options for managing acute heart rhythm episodes outside of a clinical setting. The company’s lead product is etripamil, a short-acting calcium channel blocker formulated as a nasal spray. It is designed for self-administration to treat episodes of paroxysmal supraventricular tachycardia, a condition involving sudden episodes of abnormally fast heart rate.
Receive News & Ratings for Sol-Gel Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sol-Gel Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
